PFE Jun 2026 25.000 call
| Previous close | 5.77 |
| Open | 5.75 |
| Bid | 5.20 |
| Ask | 5.60 |
| Strike | 25.00 |
| Expiry date | 2026-06-18 |
| Day's range | 5.58 - 5.75 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.48k |
- Reuters
Pfizer reports patient death in Duchenne gene therapy study
A young boy died due to a cardiac arrest in a mid-stage trial that tested Pfizer's experimental gene therapy for a muscle-wasting disorder called Duchenne muscular dystrophy (DMD), the drugmaker told Reuters on Tuesday. "A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study," a company spokesperson told Reuters in an emailed response. The trial tested boys 2 years to less than 4 years of age with DMD, a genetic muscle wasting disorder in which most patients lack the protein dystrophin which keeps muscles intact.
Insider Monkey15 Best S&P 500 Dividend Stocks To Buy Now
In this article, we discuss 15 best S&P 500 dividend stocks to buy now. You can skip our detailed analysis of dividend stocks in the S&P 500 and their past performance, and go directly to read 5 Best S&P 500 Dividend Stocks To Buy Now. It’s been a dynamic first quarter for the stock market. […]
Simply Wall St.Pfizer First Quarter 2024 Earnings: Beats Expectations
Pfizer ( NYSE:PFE ) First Quarter 2024 Results Key Financial Results Revenue: US$14.9b (down 19% from 1Q 2023). Net...
